Hikma stock trades above 200 day line as investors weigh latest results

Published on 09/02/2026 at 19:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hikma stock is trading above its 200 day moving average around GBX 1,615 to 1,616 as of September 1, 2026, while investors digest double digit revenue growth and higher profits from the companys latest reported period.

Hikma, GB00B128J450, Illustration mit AI erstellt.

Hikma Pharmaceuticals PLC stock (GB00B128J450) recently traded around GBX 1,615 to 1,616 as of September 1, 2026, with the share price crossing above its 200 day moving average according to a MarketBeat overview and being quoted at GBX 1,616.00 on a German stock portal citing the London listing.

Hikma stock above key technical level

According to market data compiled by MarketBeat, Hikma Pharmaceuticals shares last traded at GBX 1,615 on September 2, 2026, with around 542,086 shares changing hands and the stock price crossing above its 200 day moving average level.

A recent overview on a German stock portal reports that Hikma stock traded at GBX 1,616.00 on September 1, 2026, on its London home exchange, within a day range from GBX 1,609.00 to GBX 1,631.00 and a reported market value of about GBX 342.14 billion as of that date.

Recent fundamentals support valuation

Hikma Pharmaceuticals most recent reported first half or quarterly results, as summarized by financial portals up to mid 2026, showed that revenue in the latest period increased by double digit percentages compared to the prior year period, while operating profit and earnings per share also improved, supporting the current valuation levels.

In that latest reported period, the company recorded revenue of several billion USD equivalent, with revenue growth in the low to mid teens percent range versus the prior year period, and profitability metrics such as core operating margin and adjusted earnings per share improving by a few percentage points compared with the same period a year earlier, according to summaries on investor oriented sites.

Go deeper

More background on Hikma Pharmaceuticals

Get further company news and regulatory filings for Hikma Pharmaceuticals and follow how the stock develops over time on our dedicated topic page.

All Hikma stock news at ad hoc news Investor Relations

Hikma injectable products as a growth driver

One of Hikma Pharmaceuticals key business lines is its portfolio of injectable medicines, including a broad range of generic injectable products used in hospitals and clinics, which have historically contributed a substantial share of the companys revenue and have shown growth in recent reporting periods as demand for hospital injectables remains robust.

Hikma stock and market view

Hikma stock, trading under ticker HIK on the London Stock Exchange, was last quoted at around GBX 1,615 to 1,616 as of September 1 and 2, 2026, according to the cited market data sources, with the share price positioned in the upper part of its recent trading range and trading volumes in the hundreds of thousands of shares per day.